Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
Externe link voor Pharvaris
Grafenauweg 8
Zug, 6300, CH
J.H. Oortweg
Leiden, South Holland 2333, NL
303 Wyman St
Suite 300
Waltham, MA 02451, US
Pharvaris heeft dit gerepost
I am eager to identify a APAC Regional Clinical Lead who has experience in clinical studies, monitoring and site engagement. The suitable candidate would have at least ten years industry experience, be self motivated and able to clearly and succinctly explain study design and deliverables. If this sounds like you please let me know.
Pharvaris heeft dit gerepost
I’m thrilled to announce that I have joined the #Pharvaris team as head of BD! I’m looking forward to progressing deucrictibant as an on-demand and prophylactic option for patients with #HAE as well as continuing to build the Pharvaris pipeline.
Pharvaris heeft dit gerepost
Enjoyed a vibrant and festive gala organized by the Swiss Chemical Society (SCS): the Swiss Chemistry and Science Night 2024 #SCSN24. It was again an honour to serve as master of ceremony together with Rachel Hevey and hand over the renowned SCS Awards to the 2024 Awardees, @https://lnkd.in/dhba-qFu https://lnkd.in/dz7RUb_h A big THANK YOU to David Spichiger and his fantastic team, Céline Wittwer and Sarah Schmitz for their limitless and enthusiastic creativity in making the Swiss Chemical Society (SCS) a beacon amongst national Chemical Societies. On stage with Prof. Christian Bochet, Rachel Hevey, Agnes Zoller, PhD, David Spichiger
Pharvaris heeft dit gerepost
On September 6th, I had the opportunity to present at the Bradykinin Symposium in Berlin the highly encouraging one-year interim results from the ONCE-AID study. In this investigator-initiated, open-label study conducted at the Amsterdam UMC with Principal Investigator Danny M. Cohn, four patients with angioedema due to acquired C1-inhibitor deficiency administered deucrictibant 40 mg extended-release (XR) tablet once daily. The potential of deucrictibant as long-term prophylaxis for this patient group was shown: three patients remained attack-free from the start of treatment and the fourth patient has been attack-free for over a year, following a single attack shortly after treatment initiation. Deucrictibant XR tablet was well tolerated, with no drug-related adverse events.
Pharvaris is saddened by the passing of Professor Marcus Maurer, a distinguished leader in the fields of dermatology, allergy, and hereditary angioedema (HAE) research and clinical practice. Prof. Maurer was pivotal in advancing knowledge and care of HAE, also contributing to numerous clinical programs for HAE therapies. His medical knowledge, scientific rigor, commitment to patient care, and proactive collaboration with his partners, including Pharvaris, will have lasting impacts on the advancement of care and of new treatment options for people living with HAE. We will miss Prof. Maurer dearly and are forever grateful for his contributions to the HAE community. We extend our sincerest condolences to his family, friends, colleagues, and patients.
Professor Marcus Maurer (1966-2024) We are devastated by the unimaginable and untimely passing of Professor Marcus Maurer, a giant in the angioedema/urticaria realm. Nobody could ever duplicate the vision, brilliance, determination, leadership, and special interpersonal skills that typified our dear colleague and friend. Marcus was the driving force behind creating the GA2LEN & HAEi network of Angioedema Centers of Reference and Excellence (ACARE). The 102 ACARE centers throughout the globe serve as a testament to his belief in the benefit of establishing strong bonds between patients and the physicians who provide clinical care and conduct groundbreaking research. Marcus held board certifications in Dermatology and Allergology and published over 850 articles and 55 books and chapters that made significant contributions to allergy research and treatment. Among his many remarkable attributes, Marcus had an instinctual skill for collaboration and bringing out the best in the clinicians, scientists, and patient advocates he worked with. His legacy is the dramatic scientific and patient care improvements seen in the fields of angioedema and urticaria. Our global HAEi community extends its heartfelt condolences to the Maurer family. Your mantra of “Never Giving Up” motivates us to continue moving forward despite our extreme sadness. Words cannot express how much we will miss our beloved Marcus. Your HAEi Family 🖤
We have been selected as a finalist for the Post IPO of the Year category of the European Lifestars Awards - Celebrating Life Science Leaders, recognizing the significance of our $300 million underwritten offering that closed last December. In addition, our CEO, Berndt Modig, is a finalist for the Public Company CEO of the Year category emphasizing his unwavering commitment to leading Pharvaris through the advancement of our #HereditaryAngioedema (#HAE) pipeline. Winners of each category will be announced on November 18. Learn more: https://lnkd.in/dNeDbkCx
In case you missed it, we shared data for our lead product candidate, deucrictibant, at the #2024BradykininSymposium. It was wonderful connecting with industry professionals who share our passion for advancing the treatment of #HereditaryAngioedema. Thank you to GA²LEN e.V. for hosting our team: Anne Lesage, Giorgio Giannattasio, MD, PhD, Justin Bush, Jolanta Skarbaliene, PhD Evangelia Pardali Ming Nieves Crespo Alcarria Juan Bravo Joan Mendivil Martin Umar Katbeh, MA, PhD Mary Burke Uhlenhopp Nicolas, Grit Zahn, Mike Somers, Melissa Zonneveld-Mulder, Leandri Heystek, Jochen Knolle.
Pharvaris is expanding its reach to include X. You can now follow us on LinkedIn, Facebook, and X for updates from the company, key insights from executives, and links to resources. Pharvaris remains committed to pioneering science for patient choice. Follow us on X, here: https://lnkd.in/eaNHM_Ut
In case you missed it, our new data that was presented at the 2024 Bradykinin Symposium was recently featured in an Angioedema News article. Findings from the open-label extension portions of our Phase 2 clinical trials shows that our lead therapeutic candidate has sustained benefits for both prophylactic and on-demand treatment of #HereditaryAngioedema (HAE). Check out the article to learn more: https://lnkd.in/eK_Nr2jy
Pharvaris' Christophe Sutin, Associate Director, Clinical Supplies and IRT Lead, is participating in a panel titled "Comparing / Contrasting Sponsor Approaches to IRT" at Informa Connect Life Sciences' #IRT2024
How are your peers leveraging IRT to maximize their clinical supply strategies and advance clinical research? Join leading industry experts from Alexion Pharmaceuticals, Inc., Pharvaris and YPrime as they compare and contrast different sponsor approaches to IRT to unlock success strategies for optimizing your clinical research. Gain leading large pharma, SME pharma & solution provider perspectives and raise your questions for direct feedback from: - Imran Shakur, Director, IRT and Technology Lead, Clinical Supply Management at Alexion - Christophe Sutin, Associate Director, Clinical Supplies and IRT Lead at Pharvaris - Jon Paras, Senior Vice President, IRT Strategy at YPrime Ready to be inspired? 👉Register today: https://lnkd.in/gahFDDuD 📑View the agenda to learn more: https://lnkd.in/gCtFcSuG #IRT2024 #InteractiveResponseTechnologies #ClinicalSupply #ClinicalOperations #ClinicalResearch #Pharmaceuticals #Biotech
Laatste ronde
Vermogen na beursgangUS$ 300.000.000,00